[{"orgOrder":0,"company":"1cBio","sponsor":"Alesta Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"ALE1","moa":"PPi","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"1cBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"1cBio \/ Alesta Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"1cBio \/ Alesta Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by 1cBio

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Hospitalar
                          Not Confirmed
                          Hospitalar
                          Not Confirmed

                          Details : Alesta will develop, commercialize, and manufacture OC-1 (also known as ALE1), an orally active therapeutic candidate for hypophosphatasia (HPP).

                          Product Name : OC-1

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          January 08, 2025

                          Lead Product(s) : ALE1

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Preclinical

                          Sponsor : Alesta Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank